Lineage Cell Therapeutics (LCTX) Q2 FY26 earnings call

Lineage Cell Therapeutics is strategically leveraging its AlloSCOPE manufacturing platform to rapidly expand its internally-owned pipeline, dubbed Lineage 3.0, focusing on assets with significant competitive advantages and clear clinical signals. While awaiting progress on the OpRegen program with Roche, the company is advancing COR1, ILT1, and ReSonance, and re-evaluating OPC1 for chronic patient populations, aiming for efficient capital deployment and long-term value creation.